{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:04:47Z","timestamp":1793466287677,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Disulfiram, an FDA-approved medication for AUD, has shown significant potential as a repurposed drug in therapeutic areas including oncology and infectious diseases. The purpose of study is to analyze adverse events (AEs) associated with disulfiram by examining the FAERS database, with a focus on understanding its safety profile in both traditional and emerging applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AE reports concerning disulfiram in the FAERS database from the fourth quarter of 2002 to the third quarter of 2023 were extracted. Various signal detection methods, including ROR, PRR, BCPNN, and MGPS, were used to detect and categorize adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study collected 52,159,321 AE reports, with 508 reports primarily suspecting disulfiram, identifying 104 Preferred Terms (PTs) across 25 System Organ Classes (SOCs). Major categories of AEs included off label use, psychiatric symptom, liver transplant, and polyneuropathy, with off label use being notably the most reported issue. Strong and new potential AEs were identified, including neurological and psychiatric issues like hypomania, delirium, and vocal cord paralysis; cardiac issues such as electrocardiogram st segment depression; and off label use-related issues like Jarisch-Herxheimer reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Disulfiram poses risks of various adverse reactions while having promise as a \u201crepurposed\u201d agent. In clinical applications, practitioners should closely monitor occurrences of hepatobiliary disorders, psychiatric disorders, and nervous system disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2024.1498204","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T01:15:48Z","timestamp":1731978948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230488","article-title":"Overview of alcohol use disorder","volume":"180","author":"Kranzler","year":"2023","journal-title":"Am J Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030524","article-title":"Disulfiram: mechanisms, applications, and challenges","volume":"12","author":"Lanz","year":"2023","journal-title":"Antibiotics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00047","article-title":"Survey of addiction specialists\u2019 use of medications to treat alcohol use disorder","volume":"11","author":"Ehrie","year":"2020","journal-title":"Front Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120868","article-title":"Repurposing\u201d disulfiram in the treatment of lyme disease and babesiosis: retrospective review of first 3 years\u2019 experience in one medical practice","volume":"9","author":"Gao","year":"2020","journal-title":"Antibiotics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122701","article-title":"A strategy of \u201cadding fuel to the flames\u201d enables a self-accelerating cycle of ferroptosis-cuproptosis for potent antitumor therapy","volume":"311","author":"Huang","year":"2024","journal-title":"Biomaterials"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114609","article-title":"FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation","volume":"43","author":"Xu","year":"2024","journal-title":"Cell Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01271-1","article-title":"Phase II study of disulfiram and cisplatin in refractory germ cell tumors. The GCT-SK-006 phase II trial","volume":"40","author":"Mego","year":"2022","journal-title":"Investigational New Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4149","article-title":"Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: A randomized clinical trial","volume":"6","author":"Werlenius","year":"2023","journal-title":"JAMA Network Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.05.009","article-title":"A phase 1\/2 study of disulfiram and copper with concurrent radiation therapy and temozolomide for patients with newly diagnosed glioblastoma","volume":"120","author":"Huang","year":"2024","journal-title":"Int J Radiat Oncology Biology Phys"},{"key":"B10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12951-024-02825-6","article-title":"Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy","volume":"22","author":"Zhou","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agaa096","article-title":"Disulfiram ethanol reaction with alcohol-based hand sanitizer: an exploratory study","volume":"56","author":"Ghosh","year":"2021","journal-title":"Alcohol Alcoholism"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.10.010","article-title":"Cutaneous adverse drug reactions to psychotropic drugs and their risk factors\u2014A case-control study","volume":"29","author":"Greil","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: Implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B18","unstructured":"DailyMed \u2014 DISULFIRAM tablet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.4.459","article-title":"The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: Guidance for clinical practice","volume":"7","author":"Malcolm","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0416-y","article-title":"Safety and tolerability of pharmacological treatment of alcohol dependence: Comprehensive review of evidence","volume":"39","author":"Sinclair","year":"2016","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41572-022-00406-1","article-title":"Hazardous drinking and alcohol use disorders","volume":"8","author":"MacKillop","year":"2022","journal-title":"Nat Rev"},{"key":"B22","unstructured":"Alcoholism by country 2024"},{"key":"B23","unstructured":"Understanding alcohol use disorder | national institute on alcohol abuse and alcoholism (NIAAA)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.016","article-title":"Clinical characteristics and prognostic markers in disulfiram-induced liver injury","volume":"44","author":"Bj\u00f6rnsson","year":"2006","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2024.08.019","article-title":"Useful biomarkers for predicting poor prognosis of patients with drug-induced liver injury: A retrospective cohort study","author":"Chiang","year":"2024","journal-title":"Am J Med Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.p.118826","article-title":"Revisiting the role of neurotransmitters in epilepsy: An updated review","volume":"265","author":"Akyuz","year":"2021","journal-title":"Life Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-021-00307-2","article-title":"Treatment with dopamine \u03b2-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats","volume":"73","author":"Frankowska","year":"2021","journal-title":"Pharmacol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063153","article-title":"How to differentiate general toxicity-related endocrine effects from endocrine disruption: systematic review of carbon disulfide data","volume":"23","author":"Printemps","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001625","article-title":"Disulfiram-associated generalized tonic-clonic seizures","volume":"31","author":"Vaidyanathan","year":"2024","journal-title":"Am J Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13397","article-title":"Aversive agents: Think twice. A case report on disulfiram-induced mania","volume":"26","author":"Gonz\u00e1lez-Romero","year":"2024","journal-title":"Bipolar Disord"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128022","article-title":"Schwann cells expressing nociceptive channel TRPA1 orchestrate ethanol-evoked neuropathic pain in mice","volume":"129","author":"De Logu","year":"2019","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2011.07928.x","article-title":"Recovery of axonal myelination sheath and axonal caliber in the mouse corpus callosum following damage induced by N, N-diethyldithiocarbamate","volume":"34","author":"Utrera","year":"2011","journal-title":"Eur J Neurosci"},{"key":"B34","article-title":"Disulfiram\u2014Alcohol reaction mimicking an acute coronary syndrome","volume":"78","author":"Amuchastegui","year":"2014","journal-title":"Connecticut Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795078","article-title":"Application of disulfiram and its metabolites in treatment of inflammatory disorders","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.01.109","article-title":"Disulfiram\/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes","volume":"99","author":"Hassani","year":"2018","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MA1121-644R","article-title":"Anticancer effects of disulfiram in T-cell Malignancies through NPL4-mediated ubiquitin-proteasome pathway","volume":"112","author":"Chen","year":"2022","journal-title":"J Leukocyte Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3468","article-title":"Aldehyde dehydrogenase 2 inhibition potentiates 4-hydroxy-2-nonenal induced decrease in angiogenesis of coronary endothelial cells","volume":"38","author":"Roy","year":"2020","journal-title":"Cell Biochem Funct"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040229","article-title":"Blockade of ALDH in cisplatin-resistant ovarian cancer stem cells in vitro synergistically enhances chemotherapy-induced cell death","volume":"29","author":"Guo","year":"2022","journal-title":"Curr Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0609-0","article-title":"Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: A summary of preclinical studies","volume":"121","author":"Kita","year":"2019","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S199912","article-title":"Disulfiram inhibits epithelial-mesenchymal transition through TGF\u03b2-ERK-Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis","volume":"11","author":"Bu","year":"2019","journal-title":"Cancer Manage Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu","year":"2020","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2019.09.003","article-title":"Posterior reversible encephalopathy syndrome instigated by off-label disulfiram use for metastatic melanoma","volume":"61","author":"Beam","year":"2020","journal-title":"Psychosomatics"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1498204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T01:15:51Z","timestamp":1731978951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1498204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":43,"alternative-id":["10.3389\/fpsyt.2024.1498204"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1498204","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"article-number":"1498204"}}